ReviewNature protocols2026
Directional conjugation of monoclonal antibodies to nanoparticles using metal-free click chemistry.
Review in Nature protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The evolution of click chemistry: from classical reactions to next-generation platforms.RSC advances · 2026Review
- Targeted Hepatic Delivery of Bioactive Molecules via Nanovesicles: Recent Developments and Emerging Directions.Journal of personalized medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Here, we describe a practical step-by-step protocol for directional conjugation of monoclonal antibodies to polymersome nanoparticles via the Fc antibody moiety using metal-free click chemistry. This Protocol Extension details procedures for synthesis, quality control and evaluation of nanoparticle-antibody conjugates. The synthesis includes three main stages: (i) a mild oxidation of the glycosyl moiety that is present only on the Fc region of the antibody to produce functional aldehyde groups; (ii) attachment of a heterobifunctional linker, aminooxy-PEG-dibenzocyclooctyne, to the aldehyde groups in the Fc moiety; and (iii) click conjugation of the PEG-linker-modified antibodies to nanoparticles with azide functional groups. This protocol enables covalent surface conjugation of monoclonal antibodies that inherently does not involve the antigen-binding Fab region, thus minimizing the impact of the conjugation on the avidity of antibodies. In contrast, conventional conjugation methods that use amine groups of antibodies for covalent immobilization result in a random antibody orientation that can lead to a loss of the antibody's binding efficiency. The entire conjugation protocol requires ~18 h. The nanoparticle-antibody conjugates synthesized using this method are expected to display a high molecular specificity toward epitopes of the conjugated antibodies while maintaining the physicochemical properties of the core nanoparticles. The protocol described here does not require any special expertise other than general laboratory training on equipment such as a centrifuge, ultraviolet-visible spectrophotometers, dynamic light scattering, ELISA plate readers and cell culturing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.